How I treat advanced phases of CML

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Advanced phases of Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML), including accelerated and blast phases, have decreased in incidence but remain difficult to treat.
• Global disparities in diagnostic and therapeutic access contribute to the continued occurrence of advanced CML at initial presentation and disease progression.
• The evolution of risk stratification through clinical and molecular characterization is crucial for managing CML.

Purpose of the Study:

• To highlight the persistent challenges in managing advanced Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.
• To emphasize the importance of improved risk stratification for early detection and intervention.
• To discuss current and emerging therapeutic strategies for advanced CML.

Main Methods:

• Review of current literature on advanced Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.
• Analysis of the impact of diagnostic and therapeutic access limitations.
• Evaluation of risk stratification methods and combination therapy approaches.

Main Results:

• Despite advances in BCR::ABL1 kinase inhibitors, advanced Ph+ CML remains a significant clinical challenge.
• Limited access to diagnostics and therapies globally contributes to the incidence of advanced disease.
• Enhanced clinical and molecular risk stratification can improve identification and management of emerging advanced disease.

Conclusions:

• BCR::ABL1 tyrosine kinase inhibition is central to treating advanced Ph+ CML.
• Combination therapies involving chemotherapy, immunotherapy, and stem cell transplantation are essential for optimal long-term outcomes.
• Continued research and improved global access are vital for overcoming challenges in advanced Ph+ CML.